Market Overview

Morgan Keegan Maintains Market Perform Rating and $38 PT on Medtronic


A report from Morgan Keegan reiterates its Market Perform rating and $38 price target on Medtronic (NYSE: MDT).

The report states, “Medtronic's Ablation Frontiers system for ablating persistent and long-standing persistent atrial fibrillation (AF) will likely not be recommended for approval by the FDA Advisory Panel. We believe the chance could be as low as 30% that Medtronic… will be successful."

MDT closed yesterday at $33.73.

Posted-In: Morgan KeeganAnalyst Color News Reiteration FDA Analyst Ratings


Related Articles (AF + MDT)

View Comments and Join the Discussion!